DiscGenics, Inc.

IDCT for Lumbar Disc Degeneration - Medical / Health Care

SHARE

The first product candidate to utilize the Discogenic Cell platform is IDCT (rebonuputemcel).

Most popular related searches

IDCT is an allogeneic (donor-derived), non-invasive cell therapy that is being evaluated in two concurrent clinical trials in the U.S. and Japan for the treatment of adult patients with single-level mild to moderate symptomatic lumbar disc degeneration.

During treatment, a single dose of IDCT is injected into the painful disc percutaneously (non-surgically). 

Based on preclinical experience with IDCT, we hypothesize that the result will be reduced pain and disability.

Contact supplier

Drop file here or browse